Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prognosis of patients with BRCA1-associated ovarian carcinomas depends on TP53 accumulation status in tumor cells.

Gynecologic oncology - 1 Feb 2017

Rzepecka Iwona K, Szafron Lukasz M, Stys Agnieszka, Felisiak-Golabek Anna, Podgorska Agnieszka, Timorek Agnieszka, Sobiczewski Piotr, Pienkowska-Grela Barbara, El-Bahrawy Mona, Kupryjanczyk Jolanta

Abstract excerpt

OBJECTIVE: TP53 mutation is the most frequent molecular event in BRCA1-associated ovarian carcinomas. TP53 status may be a confounding factor in the evaluation of clinical importance of other proteins. We aimed to evaluate the clinical significance of BRCA1 mutations with respect to the TP53 accumulation status in 159 high-grade ovarian carcinomas. METHODS: Statistical analyses were done with the Kaplan-Meier...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to BRCA1 gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, BRCA1

Share to Genes, BRCA2

Share to Mutation

Share to Ovarian Neoplasms

Share to Prognosis

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 27939982
DOI: 10.1016/j.ygyno.2016.11.028

Genes

BRCA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prognosis of patients with BRCA1-associated ovarian carcinomas depends on TP53 accumulation status in tumor cells.PMID 27939982Read ↗

Is TP53 dysfunction required for BRCA1-associated carcinogenesis?Semantic proximity Read ↗

Determination of Both TP53 Mutation Status and the Amount of p53 Protein has Limited Diagnostic Importance for Patients with Ovarian Cancer.Semantic proximity Read ↗

The role of p53 mutation in BRCA1-associated ovarian cancer.Semantic proximity Read ↗

Differences in prognosis and efficacy of chemotherapy by p53 expression in triple-negative breast cancer.Semantic proximity Read ↗

Association Between BRCA Status and P53 Status in Breast Cancer: A Meta-Analysis.Semantic proximity Read ↗

TP53 and ovarian cancer.Semantic proximity Read ↗

TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial.Semantic proximity Read ↗

p53 in breast cancer subtypes and new insights into response to chemotherapy.Semantic proximity Read ↗

TP53 mutations in early-stage ovarian carcinoma, relation to long-term survivalSemantic proximity Read ↗

Increased frequency of TP53 mutations in BRCA1 and BRCA2 ovarian tumours.Semantic proximity Read ↗

High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.Semantic proximity Read ↗

Polymorphisms in PARP1 predict disease-free survival of triple-negative breast cancer patients treated with anthracycline/taxane based adjuvant chemotherapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.